New Issue: Orbital Catastrophe Ahead? Read Now

An Ingredient of Pot May Help People with Epilepsy

A new marijuana-derived drug may treat epileptic children, without the high

Join Our Community of Science Lovers!

A rising number of epileptic patients are using an alternative medicine to reduce their seizures. The herb in question is Cannabis sativa. Among the users are some of the almost 100,000 American children who have “intractable epilepsy,” which does not respond to standard antiseizure medications. Some parents report that marijuana helps to control their child's seizures when other standard drugs do not.

There is no pharmaceutical preparation of cannabis as a drug. Instead parents must personally buy pot at a medical marijuana dispensary—or perhaps illegally—to help their child.

The isolation of a chemical in marijuana that may be involved with tamping down seizures could soon change all that. Cannabidiol is a purified compound derived from cannabis that shows promise in treating epilepsy in both adults and children. The chemical, which also is responsible for some of the other health benefits associated with medical marijuana, is the main active ingredient in a new drug under investigation, called Epidiolex, manufactured by GW Pharmaceuticals. Epidiolex contains several other cannabinoid compounds but is formulated without tetrahydrocannabinol, the compound that makes people feel high.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


As with some approved seizure medications, researchers do not understand exactly how cannabidiol functions as an anticonvulsant. Whatever its physiological underpinnings, cannabidiol seems to work. Animal studies and preliminary investigations with human adults suggest it significantly reduces seizures and is well tolerated and safe.

Now researchers are making formal efforts to test cannabidiol in children with intractable epilepsy. A year-long clinical trial will test whether it diminishes epileptic activity in 150 children who have not been helped by standard seizure medications. If Epidiolex proves itself, it will supply additional evidence that marijuana may serve as a potential cornucopia of medical leads to be used for future drug development.

Annie Sneed is a science journalist who has written for the New York Times, Wired, Public Radio International and Fast Company.

More by Annie Sneed
Scientific American Magazine Vol 310 Issue 5This article was published with the title “Pot Ingredient for Epilepsy” in Scientific American Magazine Vol. 310 No. 5 (), p. 29
doi:10.1038/scientificamerican0514-29

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe